Groupama Asset Managment Has $159.68 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Groupama Asset Managment increased its Thermo Fisher Scientific stake by 12.5% in the fourth quarter, adding 30,562 shares to reach 275,578 shares valued at about $159.68 million.
• Institutional ownership in Thermo Fisher remains very high, with hedge funds and other institutions holding 89.23% of the stock. Several firms also made major additions, including J. Stern & Co. LLP and Norges Bank.
• Wall Street sentiment is still generally positive despite a recent HSBC downgrade: Thermo Fisher has a Moderate Buy consensus rating and an average price target of $608.95, while the company also reported earnings and revenue that topped estimates last quarter.

Groupama Asset Managment raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 275,578 shares of the medical research company's stock after acquiring an additional 30,562 shares during the quarter. Thermo Fisher Scientific comprises 2.3% of Groupama Asset Managment's investment portfolio, making the stock its 11th biggest holding. Groupama Asset Managment owned about 0.07% of Thermo Fisher Scientific worth $159,684,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. J. Stern & Co. LLP grew its stake in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,072,744,000. T. Rowe Price Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 2,183.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock worth $770,000,000 after buying an additional 1,270,643 shares during the period. Wellington Management Group LLP lifted its position in shares of Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock valued at $1,309,292,000 after acquiring an additional 1,270,191 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Thermo Fisher Scientific by 19.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company's stock worth $4,462,550,000 after acquiring an additional 1,230,872 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TMO. HSBC downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and decreased their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. DZ Bank began coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a "buy" rating and a $610.00 price objective for the company. Jefferies Financial Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday, April 24th. Finally, Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $608.95.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $465.98 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average price of $477.34 and a 200-day moving average price of $523.72. The company has a market cap of $173.17 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.04 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.